… Lung cancer remains the leading cause of cancer deaths in … been made in the science of
non–small cell lung cancer (NSCLC). … The National Lung Screening Trial found a lung cancer …

… of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy.
… in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. …

… in the management of non-small cell lung cancer (NSCLC) with … This review will address
updates in lung cancer screening, … metastatic non-small cell lung cancer in the first-line setting …

… Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved …

… Keywords or some variation of combination keywords included nonsmall cell lung cancer
(NSCLC), locally advanced stage, resectable, unresectable, advanced stage, metastatic, …

… Risk factors for lung cancer include tobacco use, family history, radiation exposure, and
the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) …

Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in
2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite …

… and the leading cause of cancer-related death in the world, accounting for more than 1.7 …
80–85% of lung cancers are classified pathologically as non–small cell lung cancer (NSCLC), …

… the treatment of non–small cell lung cancer (NSCLC) has transformed the therapeutic
landscape in this recalcitrant disease. And yet the development of ICIs in lung cancer has taken a …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC),
developments in neoadjuvant and adjuvant treatments have been nascent by …